Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company targeting the life sciences and healthcare sector, with a focus on translating scientific innovation into commercial opportunity. The company filed a 10-K annual report with the SEC on March 31, 2025, under accession number 0001410578-25-000576, reflecting its continued reporting obligations as a public entity. TDAC operates in the life sciences SPAC space, a segment that has attracted significant sponsor interest given the persistent pipeline of clinical-stage and pre-commercial biotech targets seeking non-traditional paths to the public markets. Visit SpacDesk and sign up for full data, filings, and analytics on TDAC and hundreds of other active SPAC vehicles.